Last reviewed · How we verify

NCT05360511

Erythropoietin Gel as an Adjunct to Xenograft in the Surgical Management of Intrabony Periodontal Defects

Completed EARLY_PHASE1 Last updated 16 January 2024
What this trial tests

EARLY_PHASE1 trial testing particulate xenograft + erythropoietin gel. in Periodontal Bone Loss in 26 participants. Completed in 1 October 2023.

Timeline
1 July 2022
Primary endpoint
1 September 2023
1 October 2023

Quick facts

Lead sponsorAin Shams University
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment26
Start date1 July 2022
Primary completion1 September 2023
Estimated completion1 October 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 20 to 50, any sex, with Periodontal Bone Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate the use of erythropoietin gel as an adjunct to xenograft in the surgical management of intrabony periodontal defects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Hydrogels in the clinic: An update.
    Clegg JR, Adebowale K, Zhao Z, Mitragotri S. · · 2024 · cited 64× · PMID 39545079 · DOI 10.1002/btm2.10680

Verify or expand the search:

Other recruiting trials for Periodontal Bone Loss

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05360511.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing